



Fluzone® (Influenza Vaccine) and Influenza Immunization Update

Dan DiVito
Senior Director, Fluzone US

SANOFI PASTEUR 

Sanofi Pasteur's Vision

**A world in which
no one suffers
or dies from a
vaccine-preventable
disease.**




SANOFI PASTEUR 

Influenza is the Disease From Which We Are Furthest From Our Goal

In Children...

US Pediatric^a Deaths from Vaccine Preventable Diseases, 2004-2013



^a ≤14 years of age

^b Meningococcal meningitis

SANOFI PASTEUR 

References

1. National Vital Statistics Report, Table 10. Number of deaths from 113 selected causes by age: United States: 2004-2013

Influenza is the Disease From Which We Are Furthest From Our Goal

And in Seniors

Adults 65+ of age suffer disproportionately from influenza related morbidity and mortality¹⁻³:

15%
of the population



60%
of hospitalizations

and



90%
of deaths

SANOFI PASTEUR 

References

1. Centers for Disease Control and Prevention (CDC). MMWR. 2009;58(RR-8):1-52. 2. Poland GA, Mulligan MJ. J Infect Dis. 2009;200:161-163. 3. Thompson WW, et al. JAMA. 2004;292(11):1333-1340.

Fluzone High-Dose Vaccine: Developed to Help Better Protect Seniors Against Influenza

Primary Endpoint^a

24.2%

MORE EFFICACIOUS
compared with Fluzone vaccine
against all flu strains^{1,2}

Secondary Endpoint^b

51.1%

MORE EFFICACIOUS
compared with Fluzone
vaccine against flu caused by
similar strains^{1,2}



^a Laboratory-confirmed, protocol-defined, influenza-like illness caused by viral strains regardless of their antigenic similarity to vaccine strains.

^b Culture-confirmed influenza caused by viral types/subtypes antigenically similar to the vaccine strains in association with a modified CDC-defined ILI

SANOFI PASTEUR 


References

1. Fluzone High-Dose vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2015. 2. DiazGranados et al. N Engl J Med 2014;371:635-645.

Fluzone High-Dose: Becoming Standard-of-Care for Influenza Immunization of Seniors

Expected 2016-17 Immunization Status for Americans ≥65 Years of Age

1/3
of US seniors
won't receive an
influenza vaccine



60%
of immunized
seniors expected to
receive Fluzone High-
Dose vaccine in 2016

SANOFI PASTEUR 

Sources: Census data, CDC published immunization rate, and company internal estimates

Sanofi Pasteur Continues to Invest in Protection from the Devastation of Influenza

- Continuing to advance the science of influenza prevention
 - **Fluzone High-Dose vaccine: Developing quadrivalent formulation and exploring expanded indication**
 - Supporting investigator-led studies of sub-populations
 - **Developing a broadly protective vaccine**
- Breaking ground on a 3rd US manufacturing facility
- Increased filling capacity for 2016-2017 season



SANOFI PASTEUR 

Ahead: The 2016-2017 Influenza Season

- Producing 65 million doses of Fluzone vaccine to help protect Americans of all ages
 - Fluzone High-Dose vaccine
 - Fluzone Quadrivalent vaccine: Pediatric Dose
 - Fluzone Quadrivalent vaccine
 - Fluzone Intradermal Quadrivalent vaccine
- Manufacturing is progressing well; investments made to improve timing of delivery
- Focused on educating healthcare providers about the devastation of influenza, especially in seniors and children



SANOFI PASTEUR 

**A world in which
no one suffers or
dies from a
vaccine-preventable
disease.**

SANOFI PASTEUR 

IMPORTANT SAFETY INFORMATION

Indication

Fluzone and Fluzone High-Dose vaccines are indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B virus contained in each vaccine. Fluzone vaccine is indicated for persons 6 months of age and older. Fluzone High-Dose vaccine is approved for use in persons 65 years of age and older.

Safety Information

The most common local and systemic adverse reactions to Fluzone and Fluzone High-Dose vaccines include pain, erythema, and swelling at the injection site; myalgia, malaise, headache, and fever (irritability, abnormal crying, drowsiness, appetite loss, and vomiting in young children receiving Fluzone vaccine). Other adverse reactions may occur. Fluzone and Fluzone High-Dose vaccines should not be administered to anyone with a known hypersensitivity (eg, anaphylaxis) to any vaccine component, including egg protein or thimerosal (the multidose vial is the only presentation containing thimerosal), or to a previous dose of any influenza vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone or Fluzone High-Dose vaccine should be based on careful consideration of the potential benefits and risks. Vaccination with Fluzone or Fluzone High-Dose vaccine may not protect all individuals.

Before administering [Fluzone](#) or [Fluzone High-Dose](#) vaccine, please see full Prescribing Information.

SANOFI PASTEUR 